Reports Q4 revenue $292.9M, consensus $280.9M. “Demand for our platform continued to accelerate in 2025, driving strong growth in volume and revenue and expanding adoption across our solutions. We are focused on building on this momentum, advancing our pipeline, and are particularly excited about the planned launch of our Caris Detect solution in the first half of 2026, which we believe represents a significant growth opportunity for Caris and an important step forward for precision medicine,” said David Dean Halbert, Founder, Chairman and CEO.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences initiated with an Outperform at Baird
- Caris Life Sciences sees Q4 revenue $281M, consensus $204.31M
- Caris Life Sciences sees FY25 revenue $800M, consensus $723.42M
- Caris Life Sciences partners with Everlywell to launch Caris Detect
- Caris Life Sciences price target lowered to $38 from $40 at Evercore ISI